AVLN vs PRLD
AVLN: Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases. PRLD: An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
Side-by-side fundamentals
| Metric | AVLN | PRLD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.72 | $3.92 | |
| Market cap as of 2026-07-23 | $1.3B | $313M | |
| Net margin as of 2026-07-23 | n/a | -278.5% | |
| Operating margin as of 2026-07-23 | n/a | -310.7% | |
| ROE as of 2026-07-23 | -63.8% | -74.6% | AVLN higher |
| ROA as of 2026-07-23 | -57.2% | -39.3% | PRLD higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.00 | PRLD lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +41.0% | |
| Beta as of 2026-07-23 | -0.12 | 0.94 | |
| 1-year return as of 2026-07-22 close | -1.6% | +379.8% | PRLD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.